Herve Lang

Title: Herve Lang: Innovator in Renal Cell Carcinoma Treatment

Introduction

Herve Lang is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of medical research, particularly in the treatment of renal cell carcinoma (RCC). His innovative approach focuses on the use of PTHrP antagonists, which has the potential to change the landscape of cancer treatment.

Latest Patents

Herve Lang holds a patent for the "Use of PTHrP antagonists for treating renal cell carcinoma." This invention concerns the application of a PTHrP antagonist in preparing a pharmaceutical composition aimed at treating RCC in mammals, especially in human subjects. The invention is particularly valuable for inhibiting or reducing tumor growth and metastasis formation in kidney cancer, with specific implications for metastatic developments in the lung and liver. He has 1 patent to his name.

Career Highlights

Throughout his career, Herve Lang has worked with esteemed institutions such as the Hôpitaux Universitaires de Strasbourg and the National Institute of Health and Medical Research. His work in these organizations has allowed him to advance his research and contribute to significant medical advancements.

Collaborations

Herve Lang has collaborated with notable colleagues, including Eric Schordan and Jean-Jacques Helwig. These partnerships have enriched his research and expanded the impact of his work in the medical field.

Conclusion

Herve Lang's innovative contributions to the treatment of renal cell carcinoma highlight his role as a significant inventor in the medical research community. His work continues to inspire advancements in cancer treatment and offers hope for improved patient outcomes.